Loading...
•
Dec 31, 2024
TransMedics Q4 2024 Earnings Report
TransMedics reported strong financial results for the fourth quarter and full year of 2024, driven by increased utilization of its Organ Care System and logistics services.
Key Takeaways
TransMedics reported a 50% increase in total revenue to $121.6 million in Q4 2024, with net income reaching $6.9 million. For the full year, revenue grew 83% to $441.5 million, and net income was $35.5 million.
Total revenue for Q4 2024 increased by 50% to $121.6 million compared to Q4 2023.
Net income for Q4 2024 was $6.9 million, or $0.19 per diluted share.
Full year 2024 total revenue increased by 83% to $441.5 million compared to full year 2023.
Full year 2024 net income was $35.5 million, or $1.01 per diluted share.
Revenue by Segment
Forward Guidance
TransMedics expects total revenue for the full year 2025 to be in the range of $530 million to $552 million, representing 20% to 25% growth compared to the company's prior year revenue.
Positive Outlook
- Expected total revenue growth of 20% to 25% for full year 2025.
- Continued focus on expanding access and improving clinical outcomes for organ transplants.
- Commitment to building infrastructure to capitalize on highly differentiated technology.
- Ongoing investment in the NOP network to prepare for future growth.
- No evidence of misconduct identified in independent review of business practices.
Challenges Ahead
- Potential fluctuations in financial results from quarter to quarter.
- Risks related to attracting, training, and retaining key personnel.
- Need to raise additional funding and ability to obtain it on favorable terms.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...